Jacobson Pharma
Jacobson Pharma Corporation Limited, commonly known as Jacobson Pharma, is a prominent player in the pharmaceutical industry, headquartered in Hong Kong (HK). Founded in 2015, the company has rapidly established itself as a leader in the development, manufacturing, and distribution of generic and proprietary pharmaceuticals across Asia and beyond. Specialising in a diverse range of therapeutic areas, Jacobson Pharma offers a unique portfolio of high-quality products, including prescription medications and over-the-counter solutions. The company is recognised for its commitment to innovation and quality, ensuring that its offerings meet stringent regulatory standards. With a strong market position, Jacobson Pharma has achieved significant milestones, including strategic partnerships and expansions that enhance its operational capabilities. As a trusted name in the pharmaceutical sector, Jacobson Pharma continues to focus on delivering effective healthcare solutions to improve patient outcomes.
DitchCarbon Score
How does Jacobson Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jacobson Pharma's score of 22 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Jacobson Pharma's reported carbon emissions
In 2024, Jacobson Pharma reported total carbon emissions of approximately 19,800,590 kg CO2e. This figure includes 8,415,300 kg CO2e from Scope 1 emissions, 11,136,260 kg CO2e from Scope 2 emissions, and 249,020 kg CO2e from Scope 3 emissions. In 2023, the company's total emissions were about 63,219,040 kg CO2e, with Scope 1 contributing 39,452,960 kg CO2e, Scope 2 at 23,612,700 kg CO2e, and Scope 3 at 153,380 kg CO2e. The previous year, 2022, saw total emissions of approximately 60,328,700 kg CO2e, with Scope 1 emissions at 37,247,570 kg CO2e, Scope 2 at 23,114,050 kg CO2e, and Scope 3 at 151,470 kg CO2e. The data indicates a significant reduction in emissions from 2022 to 2024, showcasing Jacobson Pharma's commitment to lowering its carbon footprint. However, there are currently no specific reduction targets or climate pledges disclosed by the company. Overall, Jacobson Pharma's emissions data reflects a proactive approach to managing carbon emissions, aligning with industry standards for climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 34,398,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 18,749,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 136,000 | 000,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jacobson Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
